#United States #Saddle Brook #Everwell Health #Nutrition21 #Celadrin

Everwell Health Expands Its Horizons with New Cetylated Fatty Acid Technology

In a strategic move set to reshape nutritional offerings for both humans and animals, Everwell Health, alongside its subsidiary Nutrition21, has recently finalized the acquisition of proprietary cetylated fatty acid technology from Things of That Nature, Inc. This acquisition not only encompasses a valuable brand known as Celadrin but also unlocks a potential goldmine of innovative functional ingredients tailored for the supplement, food and beverage, and cosmetic markets.

The Significance of the Acquisition

Acquiring all ingredient assets from Things of That Nature, Inc. represents a major breakthrough for Everwell Health, enhancing its product portfolio and fostering an expansive range of applications in the wellness sector. Celadrin is renowned globally for its effectiveness in promoting joint comfort, enhancing mobility, and even supporting skincare solutions, making it a versatile ingredient for varying market needs.

Steve Rosenman, the CEO of Everwell Health, emphasized the milestone nature of this acquisition, stating, "We’re committed to developing premium and effective ingredients that deliver exceptional value to both our customers and consumers." He further adds that the newly acquired technology aligns seamlessly with the company’s mission to provide unique ingredients that support both human health and the health of companion animals.

Consumer Insights and Market Trends

Research indicates a growing consumer preference towards products that enhance mobility and promote skin health. In the last two years, the market has seen considerable growth in joint health supplements, with a Compound Annual Growth Rate (CAGR) of nearly 11% between 2022 and 2024. Similarly, skincare product launches have surged by 13% CAGR during the same period.

Jordan Miller, Vice President of Marketing at Everwell Health, remarked, "Consumers are increasingly seeking healthy aging solutions earlier in life to maintain physical function and youthful skin appearance. In fact, 54% of North American consumers express an interest in mobility products even when they don’t exhibit symptoms."

This shift towards wellness has created a robust opportunity for brands like Everwell Health to innovate and cater to the rising consumer demands, ensuring they remain at the forefront of health solutions that address both mobility and skin-related concerns.

Celadrin’s Proven Effectiveness

The Celadrin brand is particularly well-respected, backed by a number of clinical studies that attest to its efficacy in promoting joint health, flexibility, and overall comfort. Furthermore, it plays a role in skincare by helping to counteract the visible signs of aging and improve skin hydration when applied topically.

Everwell Health’s commitment not only revolves around product effectiveness but also focuses on delivering unique value propositions that resonate with consumer needs in the dietary supplements and cosmetic industries.

Existing customers will be pleased to know that the company intends to maintain business continuity while leveraging new scientific investments and enhanced marketing strategies to amplify the product’s market presence.

Future Development and Vision

As Everwell Health sets its sights on future innovations, there is a clear intention to expand the brand’s reach and impact within the health and wellness sectors, combining scientific advancements with evolving consumer preferences. The acquisition of this cetylated fatty acid technology serves as the cornerstone for strategically positioning the brand as a leader in providing effective wellness solutions, informed by rigorous scientific research.

With a dedication to championing high-quality ingredient solutions, Everwell Health reaffirms its goal of enabling people—and companion animals—to look, feel, and perform at their best.

For more information on Everwell Health and its expanding product offerings, visit www.Everwellhealth.com.